Glenmark Shares Up After USFDA Nod To Sell Rufinamide

Posted By:
Subscribe to GoodReturns

Shares in Glenmark Pharmaceuticals were trading marginally higher after the company said that it has been granted tentative approval by the US health regulator to sell Rufinamide, which is used to treat seizures caused by Lennox-Gastaut syndrome.

Glenmark Shares Up After USFDA Nod  To Sell Rufinamide
Glenmark Pharmaceuticals: Quotes, News
BSE 637.60BSE Quote5.9 (0.93%)
NSE 638.25NSE Quote5.75 (0.90%)
The stock was last trading at Rs 899 on the National Stock Exchange. Lennox-Gastaut syndrome is a form of childhood-onset epilepsy.

"Glenmark...has been granted tentative approval last week by the United States Food and Drug Administration (USFDA) for its Rufinamide tablets," the company said in a BSE filing.

The approval has been granted for the tablets in 200 mg and 400 mg strengths. Rufinamide is a therapeutic equivalent of Banzel tablets of Eisai.

Glenmark further said: "Under the terms of a settlement agreement between Glenmark and Eisai, Glenmark will be permitted to market this product in the US on May 30, 2022 or potentially earlier under certain circumstances."

Read more about: glenmark
Story first published: Thursday, May 21, 2015, 12:24 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'


Get Latest News alerts from Goodreturns